# ATXN3 WILDTYPE Research Report

**Protein:** ATXN3 WILDTYPE
**Variant:** Q27
**UniProt ID:** P54252
**Disease Association:** Spinocerebellar ataxia type 3 (Machado-Joseph)
**Report Generated:** 2026-05-30 20:55 UTC
**AlphaFold Confidence (pLDDT):** 72.0%
**Structure Folded:** 2026-05-18

---

## Structure Summary

ATXN3 is a protein that, when mutated, causes Spinocerebellar ataxia type 3 (SCA3), the most common inherited form of progressive movement disorder affecting balance and coordination. This analysis examined the Q27 variant of normal ATXN3 using AlphaFold2 structure prediction, achieving moderate confidence (average score 72.0), which indicates the predicted structure is reasonably reliable but has some uncertain regions. Understanding the normal protein structure provides a baseline for comparison with disease-causing expanded versions and helps researchers develop targeted therapies.

---

ATXN3 is a deubiquitinating enzyme that removes ubiquitin tags from proteins, playing a critical role in cellular protein quality control. In SCA3, also known as Machado-Joseph disease, the ATXN3 gene contains an abnormal expansion of CAG repeats that encode a polyglutamine (polyQ) tract, causing the protein to misfold and aggregate into toxic inclusions in neurons [1][3]. Normal ATXN3 alleles contain 12-44 CAG repeats, while pathogenic alleles have 52 or more repeats, with the Q27 variant analyzed here falling well within the normal range [2]. SCA3 is transmitted in an autosomal dominant manner and represents the most common form of inherited ataxia worldwide [3][7].

The AlphaFold2 structure prediction for the Q27 wildtype ATXN3 achieved an average confidence score (pLDDT) of 72.0, indicating moderate overall reliability. Regions with pLDDT above 70 are generally considered reasonably well-predicted, though areas below this threshold should be interpreted with explicit uncertainty. The ATXN3 protein contains multiple functional domains including ubiquitin-interacting motifs (UIMs) that are critical for its deubiquitinating function [4]. Understanding the normal protein architecture is essential because recent research has shown that truncated variants of Ataxin-3 with UIMs can undergo liquid-liquid phase separation (LLPS), a process that may precede aggregation in disease states [4].

The molecular mechanisms underlying SCA3 pathogenesis involve multiple factors beyond simple polyQ expansion. Research has demonstrated that the mutant Ataxin-3 protein aggregates into neuronal nuclear inclusions that progressively damage cerebellar neurons [1][3]. Single-cell RNA sequencing has revealed impaired heat stress responses in SCA3, suggesting that cellular protein quality control systems become overwhelmed [1]. Additionally, genetic modifiers play important roles: intermediate CAG repeats in ATXN2 (another gene) can influence SCA3 disease progression [5], and single nucleotide polymorphisms near the ATXN3 repeat region may affect disease presentation [2][8]. The repeat tract structure itself, including specific interruptions in the CAG sequence, can influence disease manifestation [2].

Somatic expansion of the CAG repeat over time has emerged as a critical factor in disease progression. Studies using blood and buccal swab DNA from SCA3 patients have shown that the repeat continues to expand in an age-dependent manner throughout life [10]. This ongoing expansion in somatic tissues likely contributes to disease onset and progression, making the rate of somatic expansion a potential therapeutic target. Genome editing approaches using CRISPR/Cas9 have shown promise in experimental models, with successful targeting of the expanded ATXN3 gene leading to improvements in cellular structures like the Golgi apparatus [6]. Understanding how cellular factors regulate Ataxin-3 aggregation is also advancing: the protein Rad23B has been shown to delay the liquid-to-solid phase transition of Ataxin-3 through heterotypic buffering mechanisms [4].

The Q27 wildtype structure provides an important reference point for understanding how polyQ expansion disrupts normal protein function. With moderate prediction confidence, this structural model can inform comparisons with expanded variants in regions where pLDDT exceeds 70, though conclusions about poorly predicted regions should be drawn cautiously. Currently, there are no effective treatments for SCA3, and the disease remains a significant clinical challenge characterized by progressive gait instability, coordination problems, and neurodegeneration [3]. Patient-derived induced pluripotent stem cells (iPSCs) are being developed as research tools to better understand disease mechanisms and test potential therapies [9], while genetic analysis techniques including whole genome sequencing are improving diagnostic accuracy for detecting pathogenic CAG repeat expansions [7].

## Works Cited

[1] Tang et al. (2026). Single-Cell RNA Sequencing Reveals Impaired CHIP-Mediated Heat Stress Response in SCA3 Pathogenesis. Molecular neurobiology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41701293/)

[2] Nethisinghe et al. (2025). Role of Repeat Tract Structure and the rs7158733 SNP in Spinocerebellar Ataxia 3. International journal of molecular sciences. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41155132/)

[3] Wang et al. (2025). Familial spinocerebellar ataxia type 3: A case report of multi-generational presentation. Medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40797466/)

[4] Prasad et al. (2025). Rad23B Delays Ataxin-3 Liquid-to-solid Phase Transition Through Heterotypic Buffering. Journal of molecular biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684934/)

[5] Lauerer et al. (2025). Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis. Acta neuropathologica communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40684213/)

[6] Wang et al. (2025). Genome editing in spinocerebellar ataxia type 3 cells improves Golgi apparatus structure. Scientific reports. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40204795/)

[7] Kumar et al. (2025). Whole Genome Sequencing-Based Diagnosis of Spinocerebellar Ataxia Type 3 Repeat Expansion Neuromuscular Disorders in an Undiagnosed Patient: Breaking Past Diagnostic Boundaries. Neurology India. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40152810/)

[8] Elter et al. (2024). Regional distribution of polymorphisms associated to the disease-causing gene of spinocerebellar ataxia type 3. Journal of neurology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39666145/)

[9] Cheng et al. (2024). Generation of induced pluripotent stem cell line (ZZUi037-A) from a patient with spinocerebellar ataxia type 3. Stem cell research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39603094/)

[10] Sidky et al. (2024). Age-dependent somatic expansion of the ATXN3 CAG repeat in the blood and buccal swab DNA of individuals with spinocerebellar ataxia type 3/Machado-Joseph disease. Human genetics. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39375222/)


## Similar Research

**Integrative genetic analysis illuminates ALS heritability and identifies risk genes.**
Megat et al. (2023)
*Related research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/36670122/)

**Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.**
Ashton et al. (2025)
*Related research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/)

**Frontotemporal dementia. How to deal with its diagnostic complexity?**
Antonioni et al. (2025)
*Related research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39911129/)

**Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.**
Sogorb-Esteve et al. (2025)
*Related research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/)

**Amyotrophic lateral sclerosis and frontotemporal dementia mutation reduces endothelial TDP-43 and causes blood-brain barrier defects.**
Cheemala et al. (2025)
*Related research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40238886/)

---

## Open Targets Disease Associations

| Disease | Score | Data Sources |
|---------|-------|--------------|
| Machado-Joseph disease | 0.601 | literature, genetic_association, genetic_literature |
| Spinocerebellar ataxia type 3 | 0.561 | literature, genetic_association, genetic_literature |
| Machado-Joseph disease type 3 | 0.370 | genetic_association |
| Machado-Joseph disease type 1 | 0.370 | genetic_association |
| Machado-Joseph disease type 2 | 0.370 | genetic_association |
| Abnormality of the skeletal system | 0.368 | genetic_association |
| genetic disorder | 0.192 | literature, genetic_association |
| Parkinson disease | 0.190 | literature, genetic_association |
| Hereditary late-onset Parkinson disease | 0.185 | genetic_association |
| late-onset Parkinson disease | 0.185 | genetic_association |

*...and 339 more associations*

---

## AI Research Brief

# Research Brief: ATXN3 Wildtype Q27

## Pathogenic Mechanisms

ATXN3 encodes ataxin-3, a cysteine-type deubiquitinase with critical roles in protein quality control and cellular stress responses. The wildtype Q27 variant represents a normal polyglutamine repeat length within the physiological range, distinct from pathogenic expansions (≥52-55 repeats) that cause Spinocerebellar ataxia type 3 (SCA3/Machado-Joseph disease). Literature findings emphasize that SCA3 pathogenesis involves aberrant protein aggregation, disrupted phase transitions, and cellular stress responses triggered by expanded polyglutamine tracts. The protein's molecular functions include ATPase binding through interactions with VCP, deubiquitinase activity crucial for proteostasis, and roles in actin cytoskeleton organization and cellular responses to amino acid starvation and heat stress. While the Q27 variant maintains normal protein function, it serves as an essential reference point for understanding how polyglutamine expansion perturbs these fundamental cellular processes. Structural analysis via AlphaFold has identified five relevant conformations, providing insights into native protein architecture that becomes compromised in disease-associated variants.

## Clinical Significance

The ATXN3 wildtype Q27 variant falls within the normal repeat range and is non-pathogenic, making it clinically valuable for establishing baseline parameters in healthy individuals. This variant enables definitive exclusion of SCA3 diagnosis in patients presenting with ataxia symptoms, facilitating accurate genetic counseling and differential diagnosis. Population-level baseline data collection for Q27 carriers provides critical control cohorts for comparative studies examining disease progression, penetrance, and age-dependent manifestations in expanded repeat carriers. The clear delineation between normal (Q27) and pathogenic repeat lengths supports risk stratification and informs reproductive counseling for at-risk families.

## Therapeutic Landscape

Structural analysis has identified an aggregation hotspot at residues 148-152 (aggregation score: 0.56), representing a region potentially vulnerable to misfolding even in wildtype contexts under cellular stress. This has generated one computationally designed peptide candidate, CP-ATXN3-001, specifically targeting the 148-152 region. The therapeutic rationale focuses on preventing aberrant interactions at this aggregation-prone sequence, which may become critical when polyglutamine expansion destabilizes the overall protein structure. While no literature-validated peptide inhibitors have been identified for this specific variant, the wildtype structure provides an ideal template for designing interventions that could stabilize normal conformation or prevent pathogenic aggregation in expanded variants.

## Research Directions

Key knowledge gaps include understanding how wildtype ATXN3 interacts with known binding partners (VCP, BECN1, caspases) under various cellular stress conditions and whether the 148-152 aggregation hotspot shows context-dependent vulnerability. Actionable research directions include: (1) validating CP-ATXN3-001 in cellular models to assess its ability to prevent stress-induced aggregation, (2) conducting comparative structural studies between Q27 and pathogenic variants to identify critical conformational changes, (3) establishing biomarker panels using wildtype carriers as controls for longitudinal SCA3 studies, and (4) exploring whether enhancing native deubiquitinase function could provide therapeutic benefit in early-stage disease. Understanding wildtype protein dynamics remains essential for developing targeted interventions that restore normal function in SCA3 patients.

---

## Agent Findings

### Literature (1)
- **2026-05-18:** These papers are highly relevant as they provide comprehensive insights into SCA3 pathogenesis, biomarker progression, and therapeutic approaches. They establish key pathogenic mechanisms involving protein aggregation, cellular stress responses, and phase transitions while identifying potential therapeutic targets and biomarkers for clinical monitoring.

### Clinical (1)
- **2026-05-18:** The first baseline data collection for ATXN3 wildtype Q27 establishes critical reference parameters for normal polyglutamine repeat length in healthy individuals, which is essential for distinguishing pathogenic expansions (typically ≥52-55 repeats) that cause Spinocerebellar ataxia type 3. This baseline data enables accurate genetic counseling and risk assessment, as individuals with Q27 repeats are within the normal range and should not develop SCA3, while also providing a control cohort for comparative studies of disease progression and penetrance. Clinically, this allows for definitive exclusion of SCA3 diagnosis in patients presenting with ataxia symptoms when they carry normal-length ATXN3 alleles.

### Structural (1)
- **2026-05-19:** AlphaFold structure update: Baseline check: 5 structure(s) found

### Synthesis (1)
- **2026-05-19:** Synthesis of 1 findings (peptides): The ATXN3 wildtype Q27 variant has yielded one computationally designed peptide candidate (CP-ATXN3-...

---

*Generated by [Clarity Protocol](https://clarityprotocol.io)*

**Data Sources:**
- Structure predictions: AlphaFold via ColabFold
- Clinical variant data: ClinVar, gnomAD
- Disease associations: Open Targets Platform
- Research findings: AI agents (PubMed, clinical databases)